Toad-Derived Psychedelic Shows Promise in Trial for Treatment-Resistant Depression

A single nasal dose of mebufotenin, a psychedelic compound found in Sonoran Desert toad venom, reduced depression symptoms for weeks in a clinical trial. The result points to a possible new approach for people whose depression hasn’t improved after multiple treatments, but it doesn’t establish how the treatment should fit into ongoing care. The size of the benefit and the lack of evidence about maintenance temper the promise.

Weeks of benefit after one dose

Researchers at AtaiBeckley, an Eli Lilly subsidiary, tested mebufotenin nasal spray in a double-blind randomized trial involving 193 adults with treatment-resistant depression. In a double-blind trial, participants and researchers assessing outcomes don’t know who received the treatment, a design intended to reduce the influence of expectations on reported results. Treatment-resistant depression generally applies when major depression persists after at least two antidepressant treatments, though that label doesn’t mean every patient has tried the same drugs or received the same care.

Participants who received eight- or 12-milligram doses showed significantly lower scores on a standard depression measure. The measure gives researchers a consistent way to track symptoms, but a change in a score isn’t the same as showing that every patient felt well or could return to normal activities. Reported side effects were mild to moderate, and improvements lasted for weeks after a single dose. That combination makes the result notable: the treatment was delivered in one day, while the reported benefit continued afterward.

“Single-day dosing with mebufotenin appears to be effective for postpartum depression — and now for difficult-to-treat depression — and the benefits are sustained with or without re-treatment for eight days to six months,” psychopharmacology researcher Chittaranjan Andrade told ScienceAlert. The trial findings appeared in the Journal of the American Medical Association. The quote places the findings alongside earlier interest in mebufotenin for postpartum depression, but the results described here concern adults with treatment-resistant depression. Those are related areas of research, not interchangeable patient groups.

This is more significant than it looks, but the distinction between a promising result and a usable treatment matters. A single-dose approach could appeal to patients who’ve had limited success with standard medication, yet the trial doesn’t tell us how many individuals will experience meaningful relief or how long that relief will last for them. A group average can conceal a wide range of outcomes.

The limits behind the result

Andrade cautioned that the average patient improved by about 30 percent. In an editorial accompanying the research, he said response and remission rates were below those typically reported for ketamine and electroconvulsive therapy. A reduction in symptoms can still matter to a patient, but it doesn’t necessarily mean the depression has lifted or that daily life has become manageable. The comparison also puts the result in context: other treatments already have a place in care for difficult-to-treat depression, and this study doesn’t show that mebufotenin is better.

The trial was the largest study of mebufotenin nasal spray to date, but it tested the compound as a standalone treatment. That leaves clinicians without evidence on when patients might switch to a conventional antidepressant, or whether mebufotenin could serve as ongoing maintenance therapy. These aren’t minor details. People with difficult-to-treat depression often need long-term care, and a treatment that helps for a limited period may raise practical questions about what happens next.

Similar treatment studies often have to answer two separate questions: whether a drug can reduce symptoms, and how clinicians can sustain that benefit safely and effectively over time. This trial offers evidence on the first question, but leaves the second open. (And this is the part most people overlook.) A positive result after one dose doesn’t, by itself, define a treatment plan for the months that follow.

If you’re working in this space, the next useful evidence will need to clarify who benefits, how durable that benefit is, and what care patients receive after the initial dose. The study’s average improvement and response and remission rates give some perspective, but they don’t settle those questions. A treatment can be promising and still require a clearer account of its place in care.

From media scare to clinical research

Mebufotenin’s connection to toads carries a long media history. Sensational reports in the late 1980s and early 1990s described a supposed “toad licking” trend, with stories claiming that people sought psychedelic compounds in amphibian secretions. Later media analysis found that reports of widespread use had spread through academic accounts before reaching mainstream outlets; how common the practice actually was remains unclear. The history is a reminder that attention around a substance can outrun the evidence about how people use it.

Decades on, research has moved beyond the folklore. A nasal spray studied under controlled conditions is a different subject from sensational claims about toad secretions, and the clinical findings should be judged on the trial’s results. Those results suggest that a single dose may deliver rapid, sustained relief for some patients. But the modest average improvement, lower response and remission rates compared with those typically reported for ketamine and electroconvulsive therapy, and lack of maintenance data leave mebufotenin’s clinical role unsettled. Potential, for now.

More on treatments: Chinese Scientists Develop Muscle Grafts That Can Be Injected Straight Under the Skin